Intralesional Injection Of Pingyangmycin Research Articles

Treatment of deep-seated facial microcystic lymphatic malformations with intralesional injection of pingyangmycin.

Treatment of microcystic lymphatic malformations (LMs) is still a great challenge to physicians in the field of managing vascular anomalies. Several kinds of treatment have been proposed for microcystic LMs, but the responses to these treatment modalities vary considerably among individuals. The aim of the study was to investigate the safety and efficacy of intralesional injection of pingyangmycin for microcystic LMs located in the deep facial region.Twenty-one consecutive patients with deep-seated facial microcystic LMs were treated with intralesional injection of pingyangmycin between March 2010 and April 2015. The patients received 2 to 8 injections, and the average session was 3.7. The therapeutic efficacy was accessed on the basis of the imaging findings and clinical measurements.Among the 21 patients, the clinical responses were excellent in 7 patients (33.33%), good in 9 patients (42.86%), fair in 3 patients (14.29%), and poor in 2 patients (9.52%). No severe side effects were encountered. Furthermore, therapeutic outcomes were significantly associated with lesion location (P = 0.006) and number of injections (P = 0.003).Our study supports that sclerotherapy with pingyangmycin is safe and effective for the treatment of deep-seated facial microcystic LMs.

Intralesional injection of Pingyangmycin plus corticosteroids may be an effective treatment for cheilitis granulomatosa

Cheilitis granulomatosa is a rare disease characterised by the recurrent labial swelling of one or both lips with the possibility of the condition to remain on a permanent basis. This kind of granulomatous, inflammatory disease may appear independently or be linked to a paralysis such as the facial and lingua plicata which then characteristic of the Melkersson–Rosenthal syndrome. Classically, a non-necrotizing granulomatous inflammation is seen at histologic examination. Many treatments have been tried. But as its high recurrence rate, the results were often disappointing. The major active component of Pingyangmycin is bleomycin A5. Currently, bleomycin has been proved to be a widely accepted treatment protocol for hemangiomas and lymphangioma. It has been proved that bleomycin could infiltrate prominently into lymphocytes and other inflammatory cells. Stromal connective tissue would proliferate markedly as the result of sclerotherapy. Oedema, lymphangiectasia and perivascular lymphocytic infiltration are always seen in cheilitis granulomatosa histologically. Therefore, we hypothesize that intralesional injection of Pingyangmycin plus corticosteroids may be a safe and effective treatment for cheilitis granulomatosa. The efficacy of this treatment modality is worthy of further investigation.

Intralesional injection of pingyangmycin is a safe and effective treatment for microcystic lymphatic malformations in the tongue

To evaluate the efficacy and safety of intralesional injection of pingyangmycin for the treatment of microcystic lymphatic malformations (LMs) in the tongue. Eighteen patients with tongue microcystic LMs were treated with intralesional injection of pingyangmycin. The concentration of the drug was 1 mg/mL with an addition of dexamethasone. Repeated injections were performed at an interval of 3–4 weeks. The results were evaluated by clinical examinations and Doppler ultrasonography scan. The follow-up period was 12 months to eight years after the last treatment and the mean follow-up time was three years. All patients received 1–8 injections (mean, 3.0 injections) for the whole course of treatment. The total dose of pingyangmycin administered was 8–64 mg (mean, 24 mg). Fifteen patients had complete response with no cosmetic or functional problems.Three patients with macroglossia had a reduction of 50–90% in the lesion size and needed secondary surgery. No serious complications were encountered. The results suggested that intralesional injection of pingyangmycin is an effective and safe treatment for microcystic LMs in the tongue, and can be used as the first-line treatment protocol.

The role of intralesional Pingyangmycin in the treatment of nasal polyp in aged population

This study is to investigate the effect of intralesional Pingyangmycin injection in nasal polyp. 82 patients with nasal polyp were treated with intralesional Pingyangmycin injection from September 2001 to September 2006. After a minimum follow-up of 2 years, 67 patients (81.7%) developed 76 to 100% regression in their lesions; 17 patients (18.3%) had 51 to 75% regression in their lesions. No changes in renal function or cytopenias were encountered and no changes were found with chest X-ray during the course of therapy. Thus, intralesional injection of Pingyangmycin seemed to be an effective, safe and inexpensive method to treat nasal polyp, especially in patients not suitable for surgeries. Key words: Pingyangmycin, nasal polyp, intralesional, aged.

Treatment of infantile hemangioma in parotid gland region with pingyangmycin injection

Objective To evaluate the clinical efficacy of pingyangmycin (PYM) injection on infantile hemangioma located in the parotid gland region. Methods Twelve patients were treated by intralesional injection of PYM. When necessary, the injections were repeated at an interval of one week, but not more than 3-4 sessions within a therapeutic period. Normally, the secondary therapeutic period was performed 1 month later. The general and local adverse responses were recorded and the clinical outcomes were assessed with a follow-up of 1 to 3 years. Results Complete clinical resolutions were achieved in 10 patients. 2 patients received one injection, 3 patients received 2 injections, 3 patients received 3 injections, and 2 patients received 4 injections. The remaining 2 patients with partial resolution received 6 and 7 injections respectively. No clinical recurrence was observed during the follow-up of 1 to 3 years. No ulcerations or postoperative sears in injection regions were presented. The function of facial nerve was remained normality in all patients. The systematic side effects included transient pyrexia and poor appetite appeared in partial patients. No allergy cases were found. Conclusion Treatment of infantile hemangioma located in parotid gland region with PYM injection reveals a high rate of complete clinical resolution, with fair cosmetic results and short treatment time, and it does not damage the facial nerve or form local scar.The treatment time of PYM injection seems to be positively related to size of the lesions. Key words: Infant; Parotid gland region; Hemangioma; Pingyangmycin (PYM); Treatment

Intralesional Pingyangmycin Treatment for Resistant Plantar Warts

Background: The diagnosis of viral warts is often straightforward, but their treatment is difficult and always takes a long time. Nowadays warts are usually treated with conventional methods including topical keratolytic agents, cryotherapy, electrosurgery and laser surgery. However, such treatments cause different complications, and the warts become recalcitrant. Objective: To investigate the effect of intralesional pingyangmycin injection for resistant plantar warts. Methods: From June 2006 to September 2008, we treated 66 patients with plantar warts by intralesional pingyangmycin injection after informed consent. Results: The lesions of 58 patients cleared (87.88%) after up to 4 treatments. The remaining 8 patients (12.12%) achieved partial clearance. No serious side effects were observed. Conclusion: Intralesional injection of pingyangmycin might be an effective, safe and generally well-tolerated treatment for plantar warts.

Intralesional injection of Pingyangmycin may be an effective treatment for epulis

Gingival epulis represents a family of benign tumors and tumorlike masses of the gingiva. A spectrum of inflammatory and other reactive changes can be observed pathologically as granulation, fibrous or vascular tissue. It may occur at any age, but most commonly found in patients at their twenties and sixties. Women are more frequently affected than men. Surgical excision or removal is the treatment of choice, and wider resection including extraction of the involved teeth and adjacent tissues is often required in order to prevent recurrence. However, wider resection may result in cosmetic and functional problems. Epulis bears some similarities with hemangioma both clinically and histopathologically. Therefore, we hypothesize that intralesional injection of Pingyangmycin may be a safe and effective treatment for epulis. The efficacy of this treatment modality is worthy of further investigation.

The role of intralesional Pingyangmycin in the treatment of venous malformation of facial and maxillary region

To investigate the effect of intralesional Pingyangmycin injection in venous malformation of facial and maxillary region. From September 2001 to October 2004, 82 patients were referred with venous malformation for intralesional Pingyangmycin injection. After a minimum follow-up of 2 years, 67 patients (81.7%) developed 76-100% regression in their lesions; 12 patients (14.6%) had 51-75% regression in their lesion; 3 patients underwent surgical excision for the residual swellings. No changes in renal function or cytopenias were encountered. No patients developed chest X-ray changes during the course of therapy. There were no mortalities. Intralesional injection of Pingyangmycin is an effective, inexpensive, and safe method in venous malformation of facial and maxillary region. We now favor Pingyangmycin sclerotherapy before considering surgical excision in all cases of venous malformation in our hospital.